Study title:
Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as-needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as-needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as-needed. A 6-month, randomised, double-blind, double-dummy, parallel-group, active-controlled, multicentre, phase IIIB study in adult and adolescent asthmatic patients.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Respiratory Tract Diseases [C08]
|
Brands: |
MAH holders: Please see report |
Assessment: |
Active substance: BUDESONIDE AND FORMOTEROL |
ATC code: |
Document link:
SD-039-0693 CSR Synopsis.pdf
|
Document date: 2011-09-15
|
Study number: SD-039-0693 |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
Y
|